StockMarketWire.com - Pharmaceutical company Futura Medical said the impact of Covid-19 had been 'limited' to date and said it had continued to make 'good progress' on regulatory submissions for its erectile dysfunction treatment in both Europe and the US. The company said regulatory submissions for its erectile dysfunction treatment, MED3000, in both Europe and the US were on track. The company also said it continued to target submission of the regulatory dossier to the FDA by the end of third quarter of 2020 for the US.

At 8:17am: [LON:FUM] Futura Medical PLC share price was +0.5p at 18.75p



Story provided by StockMarketWire.com